Skip to content
Peptigraph home

Survodutide Phase 2 trial (NCT04667377)

A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or Overweight

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
387
actual
Start
8 Mar 2021 (actual)
Primary completion
15 Sep 2022 (actual)
Sponsor
Boehringer Ingelheim
Design

Arms and doses

NCT04667377 study arms
ArmTypeInterventionsDescription
0.6 mg BI 456906ExperimentalDrug: BI 456906Not stated
Placebo groupPlacebo comparatorDrug: PlaceboNot stated
2.4 mg BI456906ExperimentalDrug: BI 456906Not stated
3.6 mg BI 456906ExperimentalDrug: BI 456906Not stated
4.8 mg BI 456906ExperimentalDrug: BI 456906Not stated
Endpoints

Primary endpoint

NCT04667377 primary outcomes
MeasureTime frame
Percentage Change in Body Weight From Baseline to Week 46Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT04667377 secondary outcomes
MeasureTime frame
Weight Loss of ≥ 5% of Baseline Weight at Week 46At baseline and at Week 46.
Weight Loss of ≥ 10% of Baseline Weight at Week 46At baseline and at Week 46.
Weight Loss of ≥ 15% of Baseline Weight at Week 46At baseline and at Week 46.
Absolute Change in Body Weight From Baseline to Week 46Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Absolute Change in Waist Circumference From Baseline to Week 46Baseline, Week 6, 12, 18, 24, 32, 40, and 46.
Absolute Change in Systolic Blood Pressure From Baseline to Week 46Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Absolute Change in Diastolic Blood Pressure From Baseline to Week 46Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT04667377.

Survodutide dose-finding in obesity without diabetes

Participants were randomised 1:1:1:1:1 to survodutide 0.6, 2.4, 3.6 or 4.8 mg or placebo weekly for 46 weeks: 20 weeks of escalation and 26 of maintenance.[2]

Planned-treatment weight changes at week 46 were -6.2% (0.6 mg), -12.5% (2.4 mg), -13.2% (3.6 mg) and -14.9% (4.8 mg), against -2.8% on placebo.[2]

Adverse events occurred in 91% of survodutide recipients and 75% of placebo recipients, mainly gastrointestinal in 75% and 42% respectively.[2]

Sources

  1. 1A Phase II, Randomized, Double Blind, Parallel Group,46 Weeks Dose-finding Study of BI 456906 Administered Once Weekly Subcutaneously Compared With Placebo in Patients With Obesity or OverweightClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.The lancet. Diabetes & endocrinology · 2024PMID 38330987Accessed 2 Oct 2026

Found an error? Report a correction.